{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"A scoping review evaluating physical and cognitive functional outcomes in cancer survivors treated with chemotherapy: charting progress since the 2018 NCI think tank on cancer and aging phenotypes","author":[{"@type":"Person","name":"Mostafa Mohamed"},{"@type":"Person","name":"Mustafa Ahmed"},{"@type":"Person","name":"AnnaLynn M Williams"},{"@type":"Person","name":"Nikesha J. Gilmore"},{"@type":"Person","name":"Po-Ju Lin"},{"@type":"Person","name":"Sule Yilmaz"},{"@type":"Person","name":"M. Jensen-Battaglia"},{"@type":"Person","name":"K. Mustian"},{"@type":"Person","name":"Michelle Janelsins"},{"@type":"Person","name":"Supriya Mohile"}],"datePublished":"2024","isPartOf":{"@type":"Periodical","name":"Journal of Cancer Survivorship"},"identifier":"https://doi.org/10.1007/s11764-024-01589-0","description":"Abstract\n Purpose\n The primary goal of this scoping review was to summarize the literature published after the 2018 National Cancer Institute think tank, “Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors,” on physical and cognitive functional outcomes among cancer survivors treated with chemotherapy. We focused on the influence of chemotherapy on aging-related outcomes (i.e., physical functional outcomes, cognitive functional outcomes, and frailty), given the known associations between chemotherapy and biologic mechanisms that affect aging-related physiologic processes.\n \n Methods\n A search was conducted across electronic databases, including PubMed, Scopus, and Web of Science, for manuscripts published between August 2018 and July 2023. Eligible studies: 1) included physical function, cognitive function, and/or frailty as outcomes; 2) included cancer survivors (as either the whole sample or a subgroup); 3) reported on physical or cognitive functional outcomes and/or frailty related to chemotherapy treatment (as either the whole sample or a subgroup); and 4) were observational in study design.\n \n Results\n The search yielded 989 potentially relevant articles, of which 65 met the eligibility criteria. Of the 65 studies, 49 were longitudinal, and 16 were cross-sectional; 30 studies (46%) focused on breast cancer, 20 studies (31%) focused on the age group 60 + years, and 17 (26%) focused on childhood cancer survivors. With regards to outcomes, 82% of 23 studies reporting on physical function showed reduced physical function, 74% of 39 studies reporting on cognitive functional outcomes found reduced cognitive function, and 80% of 15 studies reporting on frailty found increasing frailty among cancer survivors treated with chemotherapy over time and/or compared to individuals not treated with chemotherapy. Fourteen studies (22%) evaluated biologic mechanisms and their relationship to aging-related outcomes. Inflammation was consistently associated with worsening physical and cognitive functional outcomes and epigenetic age increases. Further, DNA damage was consistently associated with worse aging-related outcomes.\n \n Conclusion\n Chemotherapy is associated with reduced physical function, reduced cognitive function, and an increase in frailty in cancer survivors; these associations were demonstrated in longitudinal and cross-sectional studies. Inflammation and epigenetic age acceleration are associated with worse physical and cognitive function; prospective observational studies with multiple time points are needed to confirm these findings.\n \n Implications for cancer survivors\n This scoping review highlights the need for interventions to prevent declines in physical and cognitive function in cancer survivors who have received chemotherapy.\n ","url":"https://innscience.ca/en/community/literature/0e8e7348-da59-40aa-9547-534de2e4d24d"}